Vertex

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, Pharmaceutical, Health, VRTX, ALPN, Investment, Research program, AbbVie, Research, Development, Alpine, Inflammation, Clinical trial, Vertex, Autoimmunity, Vertex Pharmaceuticals, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
  • On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024.
  • Cash Position and Runway: As of March 31, 2024, Alpine's cash and investments totaled $362.4 million compared to $368.2 million as of December 31, 2023.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Vertex Announces First Quarter 2024 Financial Results

Retrieved on: 
水曜日, 5月 8, 2024
Cloud, Total, Risk, Depreciation, Traction, Revenue stream, Cloud computing, Chairperson, Acquisition, Adjustment, Vertex, GAAP, Bookkeeping

KING OF PRUSSIA, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • KING OF PRUSSIA, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2024.
  • For the second quarter of 2024, the Company currently expects:
    Revenues of $159 million to $162 million; and
    Adjusted EBITDA of $31 million to $33 million.
  • John Schwab, Chief Financial Officer added, “Our guidance for the second quarter reflects our continued confidence in our business.
  • Vertex will host a conference call at 8:30 a.m. Eastern Time today, May 8, 2024, to discuss its first quarter 2024 financial results.

BrightInsight Expands its Partnership with Google Cloud to Enhance the Patient Journey Through Generative AI

Retrieved on: 
火曜日, 5月 7, 2024
Cloud, HIPAA, General Data Protection Regulation, Accountability Act, GDPR, AI, Google Cloud, Health, Health care, Population Health Management, Research, Patient, Privacy, Multimedia, Vertex, SAN, Medical device

BrightInsight has embedded a Google Gemini model-powered chatbot within its Disease Management Solution to provide patients improved access to approved content.

Key Points: 
  • BrightInsight has embedded a Google Gemini model-powered chatbot within its Disease Management Solution to provide patients improved access to approved content.
  • The chatbot also serves as first-line support to more quickly and more specifically answer questions from patients around app usage.
  • Lastly, BrightInsight is also leveraging Google Cloud’s MedLM to summarize, interact with, and probe patient data from companion apps.
  • “We have invested a lot in building best-in-class technology and hiring top engineering talent,” said Ashish Agrawal, chief technology officer, BrightInsight.

Vertex Energy Announces First Quarter 2024 Results and Optimization of Hydrocracking Capacity From Renewables to Conventional Production

Retrieved on: 
木曜日, 5月 9, 2024
Oil, Gas, Alternative Energy, Energy, Other Energy, Utilities, Gasoline, KPI, Economics, Public expenditure, Conversion, Engineering, Vertex, The central science

The Company also announced that it plans to optimize its hyrdrocracking capacity between conventional production and renewables production moving forward.

Key Points: 
  • The Company also announced that it plans to optimize its hyrdrocracking capacity between conventional production and renewables production moving forward.
  • The Company will host a conference call to discuss first quarter 2024 results today, at 9:00 A.M. Eastern Time.
  • During the second quarter of 2024, Vertex is pausing renewable fuels production and redirecting the hydrocracking unit to conventional fuels and products.
  • It will use that planned turnaround to load conventional catalyst and bring the unit out of turnaround in conventional service.

Vertex Provides Preliminary Financial Results for First Quarter 2024 and Announces First Quarter Earnings Call Date

Retrieved on: 
月曜日, 4月 22, 2024
Vertex, Chairperson, Revenue stream

KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced preliminary financial results for the period ended March 31, 2024.

Key Points: 
  • KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced preliminary financial results for the period ended March 31, 2024.
  • “Vertex’s first quarter financial results were strong across our business,” noted David DeStefano, President, Chief Executive Officer, and Chairperson of the Board.
  • Net revenue retention at March 31, 2024 is expected to be between 111% and 113%, as compared to 110% at March 31, 2023.
  • Vertex will release full first quarter 2024 financial results before the market opens on Wednesday, May 8, 2024.

Vertex Energy Provides Operational Update for First Quarter 2024

Retrieved on: 
木曜日, 4月 18, 2024
Energy, Other Energy, Utilities, Oil, Gas, ULSD, Gasoline, Jet fuel, CBOB, Vertex, Oxygenate

The increase reflects better utilization in light of improving market conditions during the quarter.

Key Points: 
  • The increase reflects better utilization in light of improving market conditions during the quarter.
  • This reflects planned turnaround activity, as well as weather related supply events, that were experienced in the first quarter of 2024.
  • Operating expenses per barrel for the first quarter of 2024 are expected to total between $4.15 to $4.35 per barrel, a 10.9% improvement vs. prior expectations at the mid-point.
  • Vertex’s reported renewable diesel production for the first quarter 2024 is expected to be about 4,000 bpd, at the midpoint of the forecasted range of 3,000 to 5,000 bpd.

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Retrieved on: 
木曜日, 4月 18, 2024
Health, FDA, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, VRTX, Pain, Pregabalin, Safety, NDA, Food, New Drug Application, DPN, Sciatica, Fast track (FDA), Week, Patient, Medicine, Neuropathic pain, LSR, Vertex, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
  • Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
  • Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain.
  • The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral formulation into Phase 2 acute pain and peripheral neuropathic pain studies later this year.

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders

Retrieved on: 
木曜日, 4月 11, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, ALPN, Vertex, Advertising, Fraud, Vertex Pharmaceuticals

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders.
  • On behalf of Alpine shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Labelbox partners with Google Cloud to offer LLM human evaluation services

Retrieved on: 
水曜日, 4月 10, 2024
Cloud, Data curation, Learning, Distillation, AI, Google Cloud, LLM, Partnership, RAG, Google Sheets, Human, BigQuery, Vertex, API, SAN

Labelbox and Google Cloud partner to provide an integrated solution for LLM human evaluation as a fully managed service.

Key Points: 
  • Labelbox and Google Cloud partner to provide an integrated solution for LLM human evaluation as a fully managed service.
  • To enable teams to evaluate and ship LLM applications confidently, Labelbox has partnered with Google Cloud to provide Vertex AI platform customers an integrated solution for LLM evaluation as a fully managed service.
  • For teams looking to get the best of both worlds and combine a hybrid approach of AI-assistance with human evaluation, Google Cloud customers can now purchase a full suite of Labelbox products on the Google Cloud Marketplace.
  • The partnership between Google Cloud and Labelbox enables Vertex AI customers to receive a critical solution for enhancing how LLM products are built - by more easily injecting human evaluation and AI assistance directly into the process.